Assessing Bio-Techne (TECH) Valuation After Recent Share Price Rebound And Mixed Longer Term Returns

Recent performance snapshot

Bio-Techne (TECH) has drawn attention after a recent single day gain of 2.2%. The stock remains down about 7% over the past month and roughly 9% over the past 3 months.

See our latest analysis for Bio-Techne.

At a share price of US$50.85, Bio-Techne has seen short term momentum pick up, with a 7 day share price return of 5.74% following a weaker 30 day and year to date share price performance. The 1 year total shareholder return of 2.62% contrasts with declines over the 3 and 5 year periods.

If you are comparing Bio-Techne with other healthcare related opportunities, it may be worth scanning companies at the intersection of medicine and algorithms via the 39 healthcare AI stocks

With Bio-Techne shares sitting at US$50.85 and recent returns mixed across timeframes, the key question is whether a roughly US$7.8b life sciences business is now on sale or if the market is already pricing in future growth.

Most Popular Narrative: 17.2% Undervalued

Bio-Techne's most followed narrative points to a fair value of about $61.42 per share, compared with the recent close at $50.85, which places the stock at a moderate discount in that framework.

The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher margin core business segments and growth pillars, supporting both immediate operating margin improvement (expected 100 to 200 basis point expansion) and higher future earnings. Accelerated innovation and product launches in automated proteomic instrumentation (e.g., Leo Simple Western, Maurice) and digital platforms are driving high margin, high throughput product adoption, increasingly embedding the company's solutions in regulated pharma manufacturing workflows.

Read the complete narrative.

Curious what sits behind that valuation gap. The core of this narrative is how future revenue, profitability and share count interplay to justify that higher fair value.

Result: Fair Value of $61.42 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh the risk that tighter biotech funding or fresh trade and tariff pressure could dampen demand and squeeze margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another angle on valuation

The narrative built around analyst targets and fair value points to Bio-Techne trading at a moderate discount, but the current P/E of 72.7x tells a different story. That level sits above the Global Life Sciences average of 35x, the peer average of 62.2x, and a fair ratio of 24.3x. This introduces meaningful valuation risk if sentiment or growth expectations cool. Which signal do you trust more: the implied discount to fair value or the sizeable premium to today’s earnings?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment, now is a good time to review the numbers yourself, weigh both concerns and potential upsides, and see the full picture through 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that better match your goals, risk comfort, or income needs across different parts of the market.

• Target potential mispricing by scanning companies that appear to offer quality at a discount through the 47 high quality undervalued stocks.
• Strengthen your focus on resilience by reviewing stocks highlighted in the 63 resilient stocks with low risk scores.
• Spot under-the-radar opportunities by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com